Management

Mark Chandler, Ph.D. | Founding Director

Dr. Chandler founded Rules-Based Medicine, Inc. in 2002 and served as Chief Executive Officer and Chairman of the Board until his departure in 2004. Before heading Rules-Based Medicine, Dr. Chandler founded Luminex in May 1995, serving as Chairman of the Board and Chief Executive Officer. In 1982, he founded Inland Laboratories, Inc., which provides plant and bacterial toxins to the medical research community. As the President and CEO of Inland, Dr. Chandler received the KPMG Peat Marwick, High Technology Entrepreneur of the Year award in 1987. He received his Ph.D. in Immunology from the University of Texas Southwestern Medical School in Dallas in 1981. He is a fellow of the Explorers Club and serves on the Board of the EastWest Institute. Dr. Chandler is currently Chairman and CEO for Biophysical Corporation.



T. Craig Benson | President & CEO

Craig Benson joined Rules-Based Medicine, Inc. in January 2002 to direct its spin-off from Luminex Corporation. Until 2004, Benson also served as Chairman of the Board for Equity Resource Partners, LLC, a private investment company. From 1987 through September 2000, he was employed by Service Corporation International (NYSE: SCI), the world leader in death care-related services. During his tenure with SCI, he held various senior executive management positions, which included domestic and international merger and acquisition responsibilities, Vice-President of Marketing and Corporate Alliances, as well as President of SCI International, Ltd., SCI's International holding company. From 1990 to 1994, Benson served as President of Investment Capital Corporation, the private equity arm of SCI, which held over $350 million in assets. From 1984 to 1987, he held management positions with Pulaski Investment Corporation, a private holding company engaged in commercial and mortgage banking activities. Benson has served on the Board of Directors of various publicly held entities, including Florafax International, Tanknology Environmental, Inc., Equity Corporation International and Pinnacle Global Group, Inc. He received a BBA degree from Southern Methodist University in 1984.



Michael Spain, M.D. | Chief Medical Officer

Dr. Spain joined RBM in January 2004 as Chief Medical Officer from Luminex Corporation, where he served as Vice President, Clinical Affairs and Chief Medical Officer from March 1997. From 1994 until joining Luminex, he served as Medical Director of Laboratory Corporation of America. From 1984 to 1994, he served as Medical Director of Quest Laboratory (formerly Damon Clinical Laboratory). Following a four-year residency in pathology at Baylor University Medical Center in Dallas, he became board certified in 1984. Dr. Spain received his M.D. from the University of Texas Southwestern Medical School in Dallas in 1980.



Patrick McClain | Chief Financial Officer

Pat McClain joined RBM in July 2002. Most recently, McClain has served as Chief Financial Officer for Infinop Holdings, a software development company and Guardian On Board, a multi-national hardware and software concern. For six years, McClain directed accounting, finance and acquisitions for Sheshunoff Information Services and previously served as Vice President and Controller/CFO of two commercial banks. He began his career at Price Waterhouse where he directed audit engagements for six years. He received a BBA degree in Accounting from Ohio University, with honors, in 1979.



James P. Mapes, Ph.D. | Chief Scientific Officer

Dr. Mapes brings more than 15 years experience in the development and commercialization of diagnostic assay kits to Rules-Based Medicine. Before joining RBM, Dr. Mapes was Director of Research and Development for Luminex Corporation. Prior to Luminex, he worked for Becton Dickinson as Director of Clinical Affairs, where he was responsible for biological and clinical evaluation of new products. Previously, he was with Bayer Diagnostics, EnSys Corporation and Becton Dickinson with increasing responsibilities in research and development management. After post-doctoral training at Oxford University, Oxford, England, and Texas A&M University, he held a faculty position in the Biochemistry Department at Louisiana State University Medical Center in New Orleans. Dr. Mapes received his Ph.D. in Biochemistry at Indiana University in 1975.



Peter Amatulli | Vice President, Sales and Marketing

Mr. Amatulli has served as Rules-Based Medicine Inc.'s VP of Sales and Marketing since 2007. Prior to RBM, he served as the VP of Sales for several leading Contract Research Organizations (CROs) and Central Labs in the biopharmaceutical industry. His areas of expertise include Sales Management, Sales Operations, Sales Training and Business Development. From 1991-2006, Mr. Amatulli was instrumental in developing the global Covance Central Lab sales organization. Under his leadership, Covance's Central Lab grew to become the dominant service provider in the industry, and still holds that position today. While at Covance, Mr. Amatulli was responsible for reaching $1B in sales targets across multiple departments and sales teams. Formerly, Mr. Amatulli successfully led the global sales organizations for Kendle, MDS, Gentiae, and Hesperion, building sales teams and increasing revenue for each of those companies. Prior to that, Mr. Amatulli was President of Productive Workplace Systems. While there, he crafted and implemented the first global sales training program in the CRO industry. Mr. Amatulli graduated Cum Laude from Ohio University in 1973 with a degree in General Studies, and an emphasis in Business Administration.



Ralph L. McDade, Ph.D. | Strategic Development Officer

Ralph L. McDade is the Strategic Development Officer for Rules-Based Medicine and has held this post since the company's inception in 2002. He was formerly the Chief Scientific Officer for Luminex Corporation from 1996-2002 where he was closely involved with the development of xMAP technology. In addition, during this period Dr. McDade was instrumental in securing technology licensing agreements with over 20 strategic partners. He received his Ph.D. in Microbiology from the University of Texas Southwestern Medical School in 1980. Following post-doctoral training at The University of Connecticut Medical Center in Farmington, he held faculty positions at the Rockefeller University in New York and at Louisiana State University School of Medicine in New Orleans.



Samuel T. LaBrie, Ph.D. | Vice President of Corporate Development

Dr. LaBrie joined RBM in May 2007. He previously served as Senior Manager of Business Development for Sigma-Aldrich, where he was responsible for strategic reviews, licensing, acquisition, and equity investment projects. Dr. LaBrie led the Sigma investments in Cyntellect and Panomics. He was the Chief Scientific Officer and Co-Founder of an antibody microarray company, ProteoPlex, which was acquired by EMD Biosciences. From 1996 to 2001, he worked for Incyte Genomics in various management and research positions as Incyte grew from 150 to 1,600 employees. Dr. LaBrie received his PhD in Biology from the University of California, San Diego.



Dominic Eisinger, Ph.D. | Director, Strategic Development

Dr. Eisinger joined Rules-Based Medicine in 2006 as part of the business development management team. Prior to RBM, he was President and Director of Business Development at Multiplex Biosciences, a multiplex immunoassay development, validation and manufacturing services company he co-founded with Dr. Laurie Stephen. A noted international authority on immunoassay, he also started and directed Upstate Cell Signaling Solutions' multiplex business unit from its inception in 2000 until 2006.



Manfred W. Schmolz, Ph.D. | Managing Director and Chief Scientific Officer of EDI GmbH

Dr. Schmolz founded EDI GmbH in 1996 in Reutlingen, Germany. He provides RBM with expertise based on more than 20 years of experience in the development of innovative cell culture assay to characterise drug effects on the human immune system. While at EDI, he designed a series of highly complex Human Organo-Typic cell culture models (patent pending) for improved drug activity profiling. Before starting EDI, Dr. Schmolz was the head of an immunopharmacological lab he established at Bionorica GmbH. He previously served as head of quality assurance for two different manufacturers of in vitro diagnostics. Dr. Schmolz received his Ph.D. in Biology/Immunology at the Eberhard-Karls-University of Tübingen in 1987.



Laurie Stephen, Ph.D. | Director, Assay Development

Dr. Stephen joined RBM in 2006 where she is responsible for assay development and multiplexing. Prior to RBM, Dr. Stephen was Vice President and Director of Scientific Operations of Multiplex Biosciences. She managed Upstate Cell Signaling Solutions multiplex line of products and services from its inception in 2000 until 2006, including launching the first commercial kits for the Luminex® xMAP technology platform.



Margaret Sandefur, Ph.D. | Director of Quality Assurance

Margaret Sandefur, Ph.D., Director of Quality Assurance has been involved in Quality Assurance since the inception of Rules-Based Medicine. Dr. Sandefur has been responsible for the implementation of Rules-Based Medicine's Quality Programs for both CLIA and GLP. She is active in the Society of Quality Assurance (SQA) and is a Registered Quality Assurance Professional in Good Laboratory Practice (RQAP-GLP). Prior to her position at RBM, she served as Manager of Protein Chemistry at Luminex Corporation. Previously she worked in Development and Manufacturing of FDA 510k commercial control materials and point of care diagnostic materials at Abacus Diagnostic Systems and quality control and protein purification at QualiChem, LLC. Dr. Sandefur has a Ph.D. in Biochemistry from the University of Texas Health Science Center at San Antonio.



Dennis Denton | Director of Automation

Dennis Denton is the Director of Automation for Rules-Based Medicine and has held this position since the company's inception. He brings more than 20 years experience of software development, systems engineering and project management to the company. He held the same position for Luminex Corporation prior to joining Rules-Based Medicine. He was a lead engineer for Luminex Corporation from its inception where he played an integral role in developing the company's line of medical instruments and software. He received a BS degree in Computer Science from Texas A&M University in 1984.



Joshua L. Kemp | Director, Research and Development

Joshua L. Kemp joined Rules-Based Medicine in 2002 and serves as Director of Research and Development. He is responsible for the operation and supervision of the laboratory and has an integral role in directing and coordinating the development and validation of RBM Multi-Analyte Profiles. Prior to joining RBM, he served as Manager of Research and Development at Luminex Corporation and was involved in the development, optimization, and transfer of new bead-based surface chemistries from research to manufacturing. Mr. Kemp received his M.S. in Microbiology from Southwest Texas State University in 1996.



Anthony Barnes, Ph.D. | Senior Vice President, Diagnostics

Dr. Barnes has served as our Senior Vice President - Diagnostics since March 2010. Dr. Barnes served as our Vice President of Clinical Diagnostics from April 2009 to March 2010. Prior to joining RBM, Dr. Barnes served as co-founder and Chief Executive Officer of Oncimmune Ltd from 2003 to 2006 and President and Vice Chairman of Oncimmune (USA) LLC from 2007 to 2009. Previously, Dr. Barnes held the role of Chief Financial Officer of Biowulf Technologies from 2000 to 2002; Vice President, Commercial Operations at Immunicon from 1997 to 2000; Director, Life Science Practice, PRTM from 1995 to 1997; Senior Director, Infectious Disease and Nucleic